Cover Image

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics

Angelo Ruggiero,1 Antonio Portarapillo,1 Matteo Megna,1 Cataldo Patruno,2 Maddalena Napolitano1 1Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, 80131, Italy; 2Department of Health Sciences, University Magna Graecia of Catanzaro, Catanza...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ruggiero A (Author), Portarapillo A (Author), Megna M (Author), Patruno C (Author), Napolitano M (Author)
Format:	Book
Published:	Dove Medical Press, 2023-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
by: Giunta A, et al.
Published: (2017)

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
by: Roman M, et al.
Published: (2017)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
by: Cacciapuoti S, et al.
Published: (2023)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
by: Galluzzo M, et al.
Published: (2019)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
by: Machado Á, et al.
Published: (2018)

Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents
by: Audrey Melin, et al.
Published: (2021)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
by: Jin JQ, et al.
Published: (2023)

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate to severe plaque psoriasis
by: Paolo Dapavo, et al.
Published: (2024)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
by: Malakouti M, et al.
Published: (2016)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
by: Megna M, et al.
Published: (2022)

Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis
by: A. A. Kubanov, et al.
Published: (2019)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
by: Gisondi P, et al.
Published: (2016)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
by: Ruggiero A, et al.
Published: (2023)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
by: Fragoulakis V, et al.
Published: (2015)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
by: Potestio L, et al.
Published: (2023)

Apremilast and NB-UVB combination therapy in moderate-to-severe plaque type psoriasis
by: O. Yu Olisova, et al.
Published: (2020)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Ren V, et al.
Published: (2013)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece [Corrigendum]
by: Fragoulakis V, et al.
Published: (2015)

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
by: Megna M, et al.
Published: (2023)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
by: Johansson E, et al.
Published: (2018)

Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting
by: Alessio Gambardella, et al.
Published: (2023)

Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis
by: Giovanna Malara, et al.
Published: (2021)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
by: Martina Burlando, et al.
Published: (2021)

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa
by: Fotiadou C, et al.
Published: (2016)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023)

Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France - the POP study
by: A. P. Villani, et al.
Published: (2023)

Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
by: Andrea Chiricozzi, et al.
Published: (2023)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
by: Megna M, et al.
Published: (2024)

Disease severity in moderate‐to‐severe plaque psoriasis: Results from the Belgian REDISCOVER study
by: Tom Hillary, et al.
Published: (2024)

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
by: Emanuela Zagni, et al.
Published: (2021)

Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
by: Jinsui Zhang, et al.
Published: (2023)

Use of Methotrexate in the Treatment of Moderate to Severe Plaque Psoriasis in France: A Practice Survey
by: Fougerousse AC, et al.
Published: (2021)

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
by: Liye XIA, et al.
Published: (2024)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
by: Beck KM, et al.
Published: (2018)

Neutrophil/lymphocyte ratio as serum inflammatory biomarker in patients with moderate-to-severe plaque psoriasis
by: Maria E. Agapito-Valgas, et al.
Published: (2023)

Treatment of Atopic Dermatitis with Biologic Drugs
by: Gabriella Fabbrocini, et al.
Published: (2018)

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice
by: Yi-Teng Hung, et al.
Published: (2021)

The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
by: Nyholm N, et al.
Published: (2023)